Celcuity Stock Surges Ahead of Key FDA Decision on Cancer Drug

Celcuity (NASDAQ: CELC) shares surged 6.6% in afternoon trading on Tuesday as investors built positions ahead of a pivotal U.S. Food and Drug Administration (FDA) decision for the company's lead oncology drug candidate. The biopharmaceutical firm is awaiting a verdict on gedatolisib, with a target action date set for July 17, 2026.

Regulatory and Clinical Momentum

The anticipation is fueled by a series of positive regulatory signals from the FDA. The agency accepted Celcuity’s New Drug Application for gedatolisib for review under its Real-Time Oncology Review program, a pathway designed to expedite the evaluation of promising cancer therapies.

The drug, which targets a specific form of advanced breast cancer (HR+/HER2-/PIK3CA wild-type), has also received several key designations that underscore its potential to address an unmet medical need:

• Priority Review: Reduces the standard review timeline.
• Breakthrough Therapy: Indicates the drug may demonstrate substantial improvement over available therapy.
• Fast Track: Facilitates the development and expedites the review of drugs to treat serious conditions.

Ad

This strong regulatory standing is supported by data from the Phase 3 VIKTORIA-1 trial, which met its primary endpoint by showing a statistically significant and clinically meaningful improvement in progression-free survival for patients.

Market Outlook

An approval would mark a transformational moment for Celcuity, allowing the company to begin generating its first product revenues. According to the source, commercial launch preparations are nearly complete, positioning the company for a potential launch in the second half of 2026 should the FDA grant approval.

The stock's move was also supported by a constructive market environment, with the NASDAQ Composite gaining 0.9% on the day. Wall Street sentiment remains bullish, with nine analysts maintaining a "Strong Buy" consensus rating on the stock. The share price exhibited significant volatility, trading in a wide range between $101.09 and $113.32, which is characteristic of biotech stocks facing a major binary event like an FDA decision.